Back

IMFINZI and enfortumab vedotin receive US Priority Review for bladder cancer

Verifying
  • IMFINZI and enfortumab vedotin received US Priority Review for bladder cancer treatment.
  • The regimen combines durvalumab with neoadjuvant enfortumab vedotin.
  • The review covers patients with muscle-invasive bladder cancer.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.